<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37847518</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-905X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Clinical journal of the American Society of Nephrology : CJASN</Title><ISOAbbreviation>Clin J Am Soc Nephrol</ISOAbbreviation></Journal><ArticleTitle>BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients.</ArticleTitle><Pagination><StartPage>85</StartPage><EndPage>97</EndPage><MedlinePgn>85-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2215/CJN.0000000000000328</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is a lack of randomized controlled trial data regarding differences in immunogenicity of varying coronavirus disease 2019 (COVID-19) mRNA vaccine regimens in CKD populations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a randomized controlled trial at three kidney centers in Toronto, Ontario, Canada, evaluating the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response after third dose vaccination. Participants ( n =273) with CKD not on dialysis or receiving dialysis were randomized 1:1 to third dose 30- &#xb5; g BNT162b2 (Pfizer-BioNTech) or 100- &#xb5; g mRNA-1273 (Moderna). The primary outcome of this study was SARS-CoV-2 IgG-binding antibodies to the receptor-binding domain (anti-RBD). Spike protein (antispike), nucleocapsid protein, and vaccine reactogenicity were also evaluated. Serology was measured before third dose and 1, 3, and 6 months after third dose. A subset of participants ( n =100) were randomly selected to assess viral pseudovirus neutralization against wild-type D614G, B.1.617.2 (Delta), and B.1.1.529 (Omicron BA.1).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 273 participants randomized, 94% were receiving maintenance dialysis and 59% received BNT162b2 for initial two dose COVID-19 vaccination. Third dose of mRNA-1273 was associated with higher mean anti-RBD levels (1871 binding antibody units [BAU]/ml; 95% confidence interval [CI], 829 to 2988) over a 6-month period in comparison with third dose BNT162b2 (1332 BAU/ml; 95% CI, 367 to 2402) with a difference of 539 BAU/ml (95% CI, 139 to 910; P = 0.009). Neither antispike levels nor neutralizing antibodies to wild-type, Delta, and Omicron BA.1 pseudoviruses were statistically different. COVID-19 infection occurred in 10% of participants: 15 (11%) receiving mRNA-1273 and 11 (8%) receiving BNT162b2. Third dose BNT162b2 was not associated with a significant different risk for COVID-19 in comparison with mRNA-1273 (hazard ratio, 0.78; 95% CI, 0.27 to 2.2; P = 0.63).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with CKD, third dose COVID-19 mRNA vaccination with mRNA-1273 elicited higher SARS-CoV-2 anti-RBD levels in comparison with BNT162b2 over a 6-month period.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER" NlmCategory="UNASSIGNED">COVID-19 Vaccine Boosters in Patients With CKD (BOOST KIDNEY), NCT05022329 .</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yau</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8653-6778</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4905-1197</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Scarborough Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Christopher T</ForeName><Initials>CT</Initials><Identifier Source="ORCID">0000-0002-0947-7273</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Queenie</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Freda</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-2859-3667</Identifier><AffiliationInfo><Affiliation>Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Kento T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurtesi</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4122-7899</Identifier><AffiliationInfo><Affiliation>Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yidi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9013-0869</Identifier><AffiliationInfo><Affiliation>Clinical Trial Support, Sunnybrook Research Institute, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estrada-Codecido</LastName><ForeName>Jose</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8895-9862</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siwakoti</LastName><ForeName>Aswani</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leis</LastName><ForeName>Jerome A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-2250-4894</Identifier><AffiliationInfo><Affiliation>Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Adeera</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>British Columbia Provincial Renal Agency, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliver</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-3334-0581</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ontario Renal Network, Ontario Health, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colwill</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8979-1659</Identifier><AffiliationInfo><Affiliation>Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gingras</LastName><ForeName>Anne-Claude</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-6090-4437</Identifier><AffiliationInfo><Affiliation>Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hladunewich</LastName><ForeName>Michelle A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9227-4292</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ontario Renal Network, Ontario Health, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05022329</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>FDN 143301</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>2122-HQ-000071</GrantID><Agency>COVID-19 Immunity Task Force</Agency><Country/></Grant><Grant><GrantID>FDN 143301</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>2122-HQ-000071</GrantID><Agency>COVID-19 Immunity Task Force</Agency><Country/></Grant><Grant><GrantID>FDN 143301</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin J Am Soc Nephrol</MedlineTA><NlmUniqueID>101271570</NlmUniqueID><ISSNLinking>1555-9041</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EPK39PL4R4</RegistryNumber><NameOfSubstance UI="D000090983">2019-nCoV Vaccine mRNA-1273</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.2215/CJN.0000000000000386</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="Y">BNT162 Vaccine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090983" MajorTopicYN="Y">2019-nCoV Vaccine mRNA-1273</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="Y">Renal Dialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>C.T. Chan reports consultancy for Dialco, Medtronic, and Quanta; research funding from Medtronic through their external grant program; advisory or leadership roles for DaVita, Medtronic, and Quanta; and role as an Associate Editor of <i>CJASN</i>. K. Colwill reports an advisory or leadership role for Canadian National Proteomics Network&#x2014;Board of Directors and VP of Communications (unpaid). K. Colwill's spouse reports employment with CI Investments. A.-C. Gingras reports consultancy for 908Devices&#x2014;instrumentation for mass spectrometry/ paid; research funds from a research contract with Providence Therapeutics Holdings, Inc. (vaccine company) for other projects; no honorarium from companies, but honoraria from public organizations, including granting agencies (compensation for grant reviews), the American Society for Biochemistry and Molecular Biology, and the European Research Council; advisory or leadership roles as an advisor for the journals <i>Molecular Cell</i> and <i>Molecular Systems Biology</i> and Deputy Editor for <i>Molecular &amp; Cellular Proteomics</i>, role on the COVID-19 Immunity Task Force Immune Science and Testing working party, and role on the SABs of several international large grants (NIH P41, Horizon 2020). A.-C. Gingras chaired the Canadian Institutes of Health Research (CIHR) Institute of Genetics Advisory Board (to 2022), chairs the SAB of the National Research Council of Canada (NRC) Human Health Therapeutics Board, and is also the lead for the Functional Genomics pillar of CoVaRR-Net. M.A. Hladunewich reports research funding from Calliditas Therapeutics, Chinook Pharmaceuticals for studies in immunoglobulin A nephropathy, Ionis, Pfizer for a study in focal segmental glomerulosclerosis, and Roche for a preeclampsia study; honoraria from UpToDate; and other interests or relationships as Medical Lead for Glomerular Disease Ontario Renal Network. J.A. Leis has received payment for expert testimony upon request of hospitals of Ontario Hospital Association, the Ministry of Attorney General of Ontario, and Seneca College. A. Levin reports employment with BC Provincial Renal Agency and Providence Health Care; consultancy agreements with AstraZeneca, Bayer, Boehringer Ingelheim, Chinook Therapeutics, GSK, Janssen, Kidney Foundation of Canada, NIH, Occuryx/Certa, Otsuka, and Reata; research funding from AstraZeneca, Boehringer Ingelheim, Canadian Institute of Health Research (CIHR), CITF (Canadian Immunology Task Force), GSK, Health Research BC, Kidney Foundation of Canada, MOH BC, and Shared Care BC; honoraria from AstraZeneca, Bayer, GSK, Janssen, and NIH; advisory or leadership roles for AstraZeneca, Boehringer Ingelheim, CADTH, Chinook Therapeutics, CITF, GSK, KRESCENT (Kidney Research Scientist Core Education and National Training Program), NIDDK, Reata BC Renal (Exec Director), and Steering Committee Chair CURE Consortium; DSMB for NIDDK, Kidney Precision Medicine, U Washington Kidney Research Institute Scientific Advisory Committee; co-lead of Long Covid Web Grant; International Society of Nephrology Research Committee; and PI of CanSOLVE CKD; and other interests or relationships as CREDENCE National Coordinator from Janssen&#x2014;directed to her academic team, Executive Steering Committee AstraZeneca Clinical Trial, the Canadian Society of Nephrology, the DSMB Chair RESOLVE Trial (Australian Clinical Trial Network) ASPIRE Trial (ACTN), the International Society of Nephrology, the Kidney Foundation of Canada Steering Committee ALIGN trial, and the NIDDK CURE Chair Steering Committee. M.J. Oliver reports reports ownership interest in and is the sole owner of Oliver Medical Management Inc., which is a private corporation that licenses the Dialysis Measurement Analysis and Reporting (DMAR) software system. Oliver Medical Management Inc. is co-owner of a Canadian Patent for DMAR systems. M.J. Oliver reports honoraria from Baxter Healthcare and other interests or relationships with Ontario Health and as contracted Medical Lead at Ontario Renal Network. All remaining authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>17</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>17</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37847518</ArticleId><ArticleId IdType="pmc">PMC10843183</ArticleId><ArticleId IdType="doi">10.2215/CJN.0000000000000328</ArticleId><ArticleId IdType="pii">01277230-990000000-00264</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taji L Thomas D Oliver MJ, et al. . COVID-19 in patients undergoing long-term dialysis in Ontario. CMAJ. 2021;193(8):E278&#x2013;E284. doi:10.1503/cmaj.202601</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.202601</ArticleId><ArticleId IdType="pmc">PMC8034346</ArticleId><ArticleId IdType="pubmed">33542093</ArticleId></ArticleIdList></Reference><Reference><Citation>ERA-EDTA Council, ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021;36(1):87&#x2013;94. doi:10.1093/ndt/gfaa314</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfaa314</ArticleId><ArticleId IdType="pmc">PMC7771976</ArticleId><ArticleId IdType="pubmed">33340043</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai R, Zhang J, Zhu Y, Liu L, Liu Y, He Q. Mortality in chronic kidney disease patients with COVID-19: a systematic review and meta-analysis. Int Urol Nephrol. 2021;53(8):1623&#x2013;1629. doi:10.1007/s11255-020-02740-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11255-020-02740-3</ArticleId><ArticleId IdType="pmc">PMC7778685</ArticleId><ArticleId IdType="pubmed">33389508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing S Thomas D Balamchi S, et al. . Effectiveness of three doses of mRNA COVID-19 vaccines in the hemodialysis population during the Omicron period. Clin J Am Soc Nephrol. 2023;18(4):491&#x2013;498. doi:10.2215/CJN.0000000000000108</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.0000000000000108</ArticleId><ArticleId IdType="pmc">PMC10103340</ArticleId><ArticleId IdType="pubmed">36723290</ArticleId></ArticleIdList></Reference><Reference><Citation>Buti M Viladomiu L Jardi R, et al. . Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol. 1992;12(3):144&#x2013;147. doi:10.1159/000168436</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000168436</ArticleId><ArticleId IdType="pubmed">1415374</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau K Abe KT Naimark D, et al. . Evaluation of the SARS-CoV-2 antibody response to the BNT162b2 vaccine in patients undergoing hemodialysis. JAMA Netw Open. 2021;4(9):e2123622. doi:10.1001/jamanetworkopen.2021.23622</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.23622</ArticleId><ArticleId IdType="pmc">PMC8414193</ArticleId><ArticleId IdType="pubmed">34473256</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver MJ Thomas D Balamchi S, et al. . Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes in the maintenance dialysis population in Ontario, Canada. J Am Soc Nephrol. 2022;33(4):839&#x2013;849. doi:10.1681/ASN.2021091262</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021091262</ArticleId><ArticleId IdType="pmc">PMC8970446</ArticleId><ArticleId IdType="pubmed">35264455</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR El Sahly HM Essink B, et al. . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403&#x2013;416. doi:10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP Thomas SJ Kitchin N, et al. .; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603&#x2013;2615. doi:10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau K Chan CT Abe KT, et al. . Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. CMAJ. 2022;194(8):E297&#x2013;E305. doi:10.1503/cmaj.211881</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.211881</ArticleId><ArticleId IdType="pmc">PMC9053976</ArticleId><ArticleId IdType="pubmed">35115375</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad LJ, Chemaitelly H, Bertollini R; National Study Group for COVID-19 Vaccination. Effectiveness of mRNA-1273 and BNT162b2 vaccines in Qatar. N Engl J Med. 2022;386(8):799&#x2013;800. doi:10.1056/NEJMc2117933</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2117933</ArticleId><ArticleId IdType="pmc">PMC8796790</ArticleId><ArticleId IdType="pubmed">35045222</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira ED Kitchin N Xu X, et al. .; C4591031 Clinical Trial Group. Safety and efficacy of a third dose of BNT162b2 covid-19 vaccine. N Engl J Med. 2022;386(20):1910&#x2013;1921. doi:10.1056/NEJMoa2200674</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200674</ArticleId><ArticleId IdType="pmc">PMC9006787</ArticleId><ArticleId IdType="pubmed">35320659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall VG Ferreira VH Ku T, et al. . Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244&#x2013;1246. doi:10.1056/NEJMc2111462</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2111462</ArticleId><ArticleId IdType="pmc">PMC8385563</ArticleId><ArticleId IdType="pubmed">34379917</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon SK Hegmann KT Thiese MS, et al. .; HEROES-RECOVER Network Investigators, HEROES-RECOVER Network Investigators. Protection with a third dose of mRNA vaccine against SARS-CoV-2 variants in frontline workers. N Engl J Med. 2022;386(19):1855&#x2013;1857. doi:10.1056/NEJMc2201821</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2201821</ArticleId><ArticleId IdType="pmc">PMC9006784</ArticleId><ArticleId IdType="pubmed">35385628</ArticleId></ArticleIdList></Reference><Reference><Citation>Au WY, Cheung PP. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ. 2022;377:e069989. doi:10.1136/bmj-2022-069989</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-069989</ArticleId><ArticleId IdType="pmc">PMC9724446</ArticleId><ArticleId IdType="pubmed">35640925</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe KT Li Z Samson R, et al. . A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight. 2020;5(19):e142362. doi:10.1172/jci.insight.142362</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.142362</ArticleId><ArticleId IdType="pmc">PMC7566699</ArticleId><ArticleId IdType="pubmed">32870820</ArticleId></ArticleIdList></Reference><Reference><Citation>Colwill K Galipeau Y Stuible M, et al. . A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. Clin Transl Immunology. 2022;11(3):e1380. doi:10.1002/cti2.1380</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1380</ArticleId><ArticleId IdType="pmc">PMC8942165</ArticleId><ArticleId IdType="pubmed">35356067</ArticleId></ArticleIdList></Reference><Reference><Citation>Isho B Abe KT Zuo M, et al. . Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5(52):eabe5511. doi:10.1126/sciimmunol.abe5511</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe5511</ArticleId><ArticleId IdType="pmc">PMC8050884</ArticleId><ArticleId IdType="pubmed">33033173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau K Enilama O Levin A, et al. . Determining the longitudinal serologic response to COVID-19 vaccination in the chronic kidney disease population: a clinical research protocol. Can J Kidney Health Dis. 2023;10:20543581231160511. doi:10.1177/20543581231160511</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20543581231160511</ArticleId><ArticleId IdType="pmc">PMC10028441</ArticleId><ArticleId IdType="pubmed">36950028</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy CM Hu Q Abe KT, et al. . Humoral responses in the Omicron era following 3-dose SARS-CoV-2 vaccine series in kidney transplant recipients. Transplant Direct. 2023;9(1):e1401. doi:10.1097/TXD.0000000000001401</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TXD.0000000000001401</ArticleId><ArticleId IdType="pmc">PMC9742098</ArticleId><ArticleId IdType="pubmed">36518793</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD; Com-COV Study Group. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397(10289):2043&#x2013;2046. doi:10.1016/S0140-6736(21)01115-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01115-6</ArticleId><ArticleId IdType="pmc">PMC8115940</ArticleId><ArticleId IdType="pubmed">33991480</ArticleId></ArticleIdList></Reference><Reference><Citation>Normark J Vikstr&#xf6;m L Gwon YD, et al. . Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Engl J Med. 2021;385(11):1049&#x2013;1051. doi:10.1056/NEJMc2110716</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2110716</ArticleId><ArticleId IdType="pmc">PMC8314734</ArticleId><ArticleId IdType="pubmed">34260850</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X Shaw RH Stuart ASV, et al. .; Com-COV Study Group. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398(10303):856&#x2013;869. doi:10.1016/S0140-6736(21)01694-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01694-9</ArticleId><ArticleId IdType="pmc">PMC8346248</ArticleId><ArticleId IdType="pubmed">34370971</ArticleId></ArticleIdList></Reference><Reference><Citation>Atmar RL Lyke KE Deming ME, et al. .; DMID 21-0012 Study Group. Homologous and heterologous covid-19 booster vaccinations. N Engl J Med. 2022;386(11):1046&#x2013;1057. doi:10.1056/NEJMoa2116414</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116414</ArticleId><ArticleId IdType="pmc">PMC8820244</ArticleId><ArticleId IdType="pubmed">35081293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducloux D, Colladant M, Chabannes M, Yannaraki M, Courivaud C. Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. Kidney Int. 2021;100(3):702&#x2013;704. doi:10.1016/j.kint.2021.06.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.06.025</ArticleId><ArticleId IdType="pmc">PMC8243640</ArticleId><ArticleId IdType="pubmed">34216675</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajon R Doria-Rose NA Shen X, et al. . SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N Engl J Med. 2022;386(11):1088&#x2013;1091. doi:10.1056/NEJMc2119912</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119912</ArticleId><ArticleId IdType="pmc">PMC8809504</ArticleId><ArticleId IdType="pubmed">35081298</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS Cromer D Reynaldi A, et al. . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205&#x2013;1211. doi:10.1038/s41591-021-01377-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert PB, Donis RO, Koup RA, Fong Y, Plotkin SA, Follmann D. A covid-19 milestone attained - a correlate of protection for vaccines. N Engl J Med. 2022;387(24):2203&#x2013;2206. doi:10.1056/NEJMp2211314</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2211314</ArticleId><ArticleId IdType="pubmed">36507702</ArticleId></ArticleIdList></Reference><Reference><Citation>Montez-Rath ME Garcia P Han J, et al. . SARS-CoV-2 infection during the Omicron surge among patients receiving dialysis: the role of circulating receptor-binding domain antibodies and vaccine doses. J Am Soc Nephrol. 2022;33(10):1832&#x2013;1839. doi:10.1681/ASN.2022040504</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2022040504</ArticleId><ArticleId IdType="pmc">PMC9528334</ArticleId><ArticleId IdType="pubmed">35973733</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerman BA Gerlovin H Madenci AL, et al. . Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. Veterans. N Engl J Med. 2022;386(2):105&#x2013;115. doi:10.1056/NEJMoa2115463</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2115463</ArticleId><ArticleId IdType="pmc">PMC8693691</ArticleId><ArticleId IdType="pubmed">34942066</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>